GlassScriptPhysician profile
Stephen B Sondike
NPI 1528000650
$2,761.15
in general payments reported to CMS, 2019-2025
19 companies · $641 in 2025
The $641 reported for 2025 was more than what 95% of Adolescent Medicine (Pediatrics) providers received nationally (typical 2025 total: $99.31).
See the full distribution for Adolescent Medicine (Pediatrics)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $554 · 2020: $102 · 2021: $50.71 · 2022: $287 · 2023: $485 · 2024: $641 · 2025: $641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,768.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,767.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $959.11 | 2019-2025 | Fasenra, Tezspire |
| Glaxosmithkline, LLC. | $283.02 | 2024-2025 | Bexsero, Flulaval Quadrivalent, Menveo |
| Supernus Pharmaceuticals, INC. | $163.55 | 2025 | Qelbree |
| Merck Sharp & Dohme LLC | $141.89 | 2021-2023 | |
| Genzyme Corporation | $130.32 | 2024 | |
| Abbvie INC. | $125.00 | 2023 | Rinvoq |
| Collegium Pharmaceutical, INC. | $124.98 | 2025 | Jornay Pm |
| Csl Behring | $124.87 | 2024 | Haegarda |
| Shire North American Group INC | $124.06 | 2019 | |
| Genentech USA, INC. | $116.47 | 2024 | Xolair |
| Ironshore Pharmaceuticals INC. | $109.87 | 2019-2022 | |
| Lilly USA, LLC | $100.01 | 2025 | Ebglyss |
| Mylan Pharmaceuticals INC. | $90.08 | 2019-2022 | |
| Sobi, INC | $69.04 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.34 | 2020-2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $20.72 | 2023 | Slynd |
| Therapeuticsmd, INC. | $20.00 | 2020 | |
| Seqirus USA INC | $17.31 | 2022 | |
| Dermira, INC. | $13.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Sondike listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.